Cash position and activity update for Q4 2017

• Solid cash position of €16.3 million at December 31, 2017
• Acquisition of LYPRO Biosciences to build the first HDL-based targeted drug
delivery platform, dedicated to the immune-oncology and chemotherapy market
• First patients enter TARGET study, recently initiated to evaluate the tumor
targeting by HDL nanoparticles in patients with esophageal cancer
• Completion of patient enrollment in the Phase 3 study, TANGO, evaluating
CER-001 in HDL genetic deficiency

Toulouse, FRANCE, Lakeland, UNITED-STATES, January 25, 2018, 6.00 pm CET – CERENIS Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces its cash position at December 31, 2017 and key highlights for the 4th quarter of 2017.

Please find attached the complete press release.

---

Source: Cerenis